In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MiNA Therapeutics Ltd.

http://minatx.com

Latest From MiNA Therapeutics Ltd.

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Deal Watch Business Strategies

Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta

After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.

Deal Watch Business Strategies

China RNA Activation Venture Ractigen Looks To Clinic For Validation

A China returnee CEO has raised roughly $50m for his bioventure that is looking to clinically validate and commercialize an RNA activation platform he co-discovered while working in the US.

China Research & Development

Lilly Supports RNA R&D Push With $700m Investment In Institute For Genetic Medicine

The big pharma has a gene therapy R&D site in New York from its Prevail Therapeutics buy; the RNA-focused Boston site also will conduct drug delivery research benefitting programs at both locations.

Innovation Strategy
See All

Company Information

UsernamePublicRestriction

Register